Lucy A. Perrone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucy A. Perrone has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
Veronica Restelli
Canadian Microbiology Proficiency Testing Program (CMPT), Department of Pathology and Laboratory Medicine , University of British Columbia , Vancouver , Canada
7 shared publications- Adama Sanogo Pongathie
Direction de l'Informatique et de la Santé Digitale Sanitaire, Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle, Abidjan, Côte d'Ivoire
5 shared publications Barbara De la Salle
UK National External Quality Assessment Scheme (UK NEQAS) for Haematology , Watford , UK
5 shared publications- Casey Iiams-Hauser
Digital Initiatives Group, International Training and Education Center for Health, Department of Global Health, Schools of Public Health and Medicine, University of Washington, Seattle, WA, United States
5 shared publications - Christiane Adje-Toure
Division of Global HIV and TB, United States Centers for Disease Control and Prevention, Abidjan, Côte d'Ivoire
5 shared publications - Christoph Buchta
Austrian Association for Quality Assurance and Standardization of Medical and Diagnostic Tests (ÖQUASTA) , Vienna , Austria
5 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Springer Nature in Implementation Science Communications
Determinants of scaled implementation for electronic laboratory information systems in 27 clinical laboratories in Côte d’Ivoire: a mixed-methods study applying the Consolidated Framework for Implementation Research (CFIR)
- 21 August 2026
- Published by Springer Nature in Implementation Science Communications
Open AccessDeterminants of scaled implementation for electronic laboratory information systems in 27 clinical laboratories in Côte d’Ivoire: a mixed-methods study applying the Consolidated Framework for Implementation Research (CFIR)
- Open Access
- 31 March 2026
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 13 (1) , e76550
Enhancing Data-Driven Decision-Making in HIV Care With Viral Load and Early Infant Diagnosis Data Dashboards in Côte d’Ivoire: Qualitative Study
Background: Data dashboards are popular tools for supporting routine monitoring and decision-making in public health. Two dashboards were developed in Côte d’Ivoire to visualize laboratory data on HIV viral load (VL) and early infant diagnosis (EID) testing. Objective: This study assessed the attitudes and experiences regarding data-driven decision-making and the VL and EID dashboards among existing and potential dashboard users in Côte d’Ivoire. Methods: We conducted a qualitative study including 2 focus group discussions (FGDs) and 12 in-depth interviews (IDIs). The conceptual framework for the use of health data in decision-making guided the FGDs, and the Consolidated Framework for Implementation Research informed the IDIs. We used deductive and inductive approaches to analyze the interview data. Results: The 26 participants were from 17 organizations; 11 (42.3%) were female. The participants reported a supportive data culture that valued data-driven decision-making and external pressure from the United States President’s Emergency Plan for AIDS Relief (PEPFAR) that motivated data use. The dashboards were considered useful for monitoring performances and making decisions for service delivery and laboratory operations. Existing users used the dashboards regularly. Potential users expressed interest in the speed and ability to track progress. The participants considered the dashboards simple and straightforward compared to other analytical tools but suggested updating the dashboards more frequently and visualizing more data. Conclusion: The study highlighted the importance of supportive data culture and the potential of dashboards to promote data use. However, challenges such as limited access to the internet and equipment for potential users need to be addressed.
- 31 March 2026
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 13 (1) , e76550
Open AccessEnhancing Data-Driven Decision-Making in HIV Care With Viral Load and Early Infant Diagnosis Data Dashboards in Côte d’Ivoire: Qualitative Study
Background: Data dashboards are popular tools for supporting routine monitoring and decision-making in public health. Two dashboards were developed in Côte d’Ivoire to visualize laboratory data on HIV viral load (VL) and early infant diagnosis (EID) testing. Objective: This study assessed the attitudes and experiences regarding data-driven decision-making and the VL and EID dashboards among existing and potential dashboard users in Côte d’Ivoire. Methods: We conducted a qualitative study including 2 focus group discussions (FGDs) and 12 in-depth interviews (IDIs). The conceptual framework for the use of health data in decision-making guided the FGDs, and the Consolidated Framework for Implementation Research informed the IDIs. We used deductive and inductive approaches to analyze the interview data. Results: The 26 participants were from 17 organizations; 11 (42.3%) were female. The participants reported a supportive data culture that valued data-driven decision-making and external pressure from the United States President’s Emergency Plan for AIDS Relief (PEPFAR) that motivated data use. The dashboards were considered useful for monitoring performances and making decisions for service delivery and laboratory operations. Existing users used the dashboards regularly. Potential users expressed interest in the speed and ability to track progress. The participants considered the dashboards simple and straightforward compared to other analytical tools but suggested updating the dashboards more frequently and visualizing more data. Conclusion: The study highlighted the importance of supportive data culture and the potential of dashboards to promote data use. However, challenges such as limited access to the internet and equipment for potential users need to be addressed.
- Open Access
- 25 April 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Enhancing Data-driven Decision Making in HIV Care with Viral Load and Early Infant Diagnosis Data Dashboards in Côte d’Ivoire: A Qualitative Study (Preprint)
BACKGROUND Data dashboards are popular tools for supporting routine monitoring and decision-making in public health. Two dashboards were developed in Côte d’Ivoire to visualize laboratory data on HIV viral load (VL) and early infant diagnosis (EID) testing. OBJECTIVE This study assessed the values, attitudes, and experiences regarding data-driven decision-making and the VL and EID dashboards among existing and potential dashboard users in Côte d’Ivoire. METHODS We conducted a qualitative study including two focus group discussions (FGDs) and 12 in-depth interviews (IDIs). The Conceptual Framework for the Use of Health Data in Decision Making guided the FGDs, and the Consolidated Framework for Implementation Research informed the IDIs. We used deductive and inductive approaches to analyze the interview data. RESULTS The 26 participants were from 17 organizations; 11 (42.3%) were female. The participants reported a supportive data culture that valued data-driven decision-making and external pressure from PEPFAR that motivated data use. The dashboards were considered useful for monitoring performances and making decisions for service delivery and laboratory operations. Existing users used the dashboards regularly. Potential users expressed interest in the speed and ability to track progress. The participants considered the dashboards simple and straightforward compared to other analytical tools but suggested updating the dashboards more frequently and visualizing more data. CONCLUSIONS The study highlighted the importance of supportive data culture and the potential of dashboards to promote data use. However, challenges such as limited access to the Internet and equipment for potential users need to be addressed. CLINICALTRIAL N/A
- 25 April 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEnhancing Data-driven Decision Making in HIV Care with Viral Load and Early Infant Diagnosis Data Dashboards in Côte d’Ivoire: A Qualitative Study (Preprint)
BACKGROUND Data dashboards are popular tools for supporting routine monitoring and decision-making in public health. Two dashboards were developed in Côte d’Ivoire to visualize laboratory data on HIV viral load (VL) and early infant diagnosis (EID) testing. OBJECTIVE This study assessed the values, attitudes, and experiences regarding data-driven decision-making and the VL and EID dashboards among existing and potential dashboard users in Côte d’Ivoire. METHODS We conducted a qualitative study including two focus group discussions (FGDs) and 12 in-depth interviews (IDIs). The Conceptual Framework for the Use of Health Data in Decision Making guided the FGDs, and the Consolidated Framework for Implementation Research informed the IDIs. We used deductive and inductive approaches to analyze the interview data. RESULTS The 26 participants were from 17 organizations; 11 (42.3%) were female. The participants reported a supportive data culture that valued data-driven decision-making and external pressure from PEPFAR that motivated data use. The dashboards were considered useful for monitoring performances and making decisions for service delivery and laboratory operations. Existing users used the dashboards regularly. Potential users expressed interest in the speed and ability to track progress. The participants considered the dashboards simple and straightforward compared to other analytical tools but suggested updating the dashboards more frequently and visualizing more data. CONCLUSIONS The study highlighted the importance of supportive data culture and the potential of dashboards to promote data use. However, challenges such as limited access to the Internet and equipment for potential users need to be addressed. CLINICALTRIAL N/A
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 879-897
Behind the scenes of EQA–characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part IV – Benefits for participant laboratories
The main stakeholders in external quality assessment (EQA) programs are the participants, in whose interests these challenges are ultimately organised. EQA schemes in the medical field contribute to improving the quality of patient care by evaluating the analytical and diagnostic quality of laboratory and point-of-care tests (POCT) by independent third parties and, if necessary, pointing out erroneous measurement results and analytical or diagnostic improvement potential. Other benefits include the option of using EQA samples for other important laboratory procedures, such as the verification or validation of in vitro diagnostic medical devices (IVD-MDs), a contribution to the estimation of measurement uncertainty, a means of training and educating laboratory staff through educational EQA programmes or samples, or even for independent and documented monitoring of staff competence, such as on samples with unusual or even exceptional characteristics. Participation in an EQA scheme for beneficiaries like medical, microbiological and histo- and molecular pathology laboratories, users of POCT and self-testing systems as well as National Metrology Institutes, calibration laboratories and reference laboratories that are dedicated to specific tasks and have particular expectations of the EQA scheme are presented here.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 879-897
Behind the scenes of EQA–characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part IV – Benefits for participant laboratories
The main stakeholders in external quality assessment (EQA) programs are the participants, in whose interests these challenges are ultimately organised. EQA schemes in the medical field contribute to improving the quality of patient care by evaluating the analytical and diagnostic quality of laboratory and point-of-care tests (POCT) by independent third parties and, if necessary, pointing out erroneous measurement results and analytical or diagnostic improvement potential. Other benefits include the option of using EQA samples for other important laboratory procedures, such as the verification or validation of in vitro diagnostic medical devices (IVD-MDs), a contribution to the estimation of measurement uncertainty, a means of training and educating laboratory staff through educational EQA programmes or samples, or even for independent and documented monitoring of staff competence, such as on samples with unusual or even exceptional characteristics. Participation in an EQA scheme for beneficiaries like medical, microbiological and histo- and molecular pathology laboratories, users of POCT and self-testing systems as well as National Metrology Institutes, calibration laboratories and reference laboratories that are dedicated to specific tasks and have particular expectations of the EQA scheme are presented here.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 868-878
Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part III – EQA samples
Providers of external quality assessment (EQA) programs evaluate data or information obtained and reported by participant laboratories using their routine procedures to examine properties or measurands in samples provided for this purpose. EQA samples must offer participants an equal chance to obtain accurate results, while being designed to provide results in clinically relevant ranges. It is the responsibility of the EQA provider to meet the necessary requirements for homogeneity, stability and some other properties of the EQA items in order to offer participants a fair, reliable and technically interesting EQA experience. Thus, the samples are at the heart and in the centre of EQA and its success depends on their quality. This manuscript describes the requirements for EQA samples and the activities of EQA providers to achieve them.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 868-878
Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part III – EQA samples
Providers of external quality assessment (EQA) programs evaluate data or information obtained and reported by participant laboratories using their routine procedures to examine properties or measurands in samples provided for this purpose. EQA samples must offer participants an equal chance to obtain accurate results, while being designed to provide results in clinically relevant ranges. It is the responsibility of the EQA provider to meet the necessary requirements for homogeneity, stability and some other properties of the EQA items in order to offer participants a fair, reliable and technically interesting EQA experience. Thus, the samples are at the heart and in the centre of EQA and its success depends on their quality. This manuscript describes the requirements for EQA samples and the activities of EQA providers to achieve them.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 898-915
Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part V – Benefits for stakeholders other than participants
External quality assessment (EQA) enhances patient safety through the evaluation of the quality of laboratory-based and point of care testing. Regulatory agencies and accreditation organizations utilize the results and the laboratory’s response to them as part of assessing the laboratory’s fitness to practice. In addition, where EQA samples are commutable and the assigned value has been determined using reference measurement procedures (RMPs), EQA data contributes to the verification of metrological traceability of assays as part of the post-market surveillance of in vitro diagnostic (IVD) medical devices (IVD-MDs). More broadly, the scientific and medical communities use EQA data to demonstrate that medical laboratory examination procedures are fit for clinical purposes, to evaluate common reference intervals, and inclusion of data in clinical databases. Scientific groups, the IVD industry, reference laboratories and National Metrology Institutes can work with EQA providers to identify measurands, which should urgently be supported by the development of reference materials or methods. The ability of health systems to respond effectively to fast-evolving medical challenges, such as the Coronavirus Disease-19 (COVID-19) pandemic, is reliant on EQA to demonstrate confidence in the performance of new laboratory methods and testing services. EQA providers are uniquely positioned to assess the performance of IVD-MDs in addition to individual laboratories and testing sites. Although the primary focus of EQA providers remains the improvement of the performance of individual laboratories, there are many stakeholders who benefit from EQA performance data.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 898-915
Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part V – Benefits for stakeholders other than participants
External quality assessment (EQA) enhances patient safety through the evaluation of the quality of laboratory-based and point of care testing. Regulatory agencies and accreditation organizations utilize the results and the laboratory’s response to them as part of assessing the laboratory’s fitness to practice. In addition, where EQA samples are commutable and the assigned value has been determined using reference measurement procedures (RMPs), EQA data contributes to the verification of metrological traceability of assays as part of the post-market surveillance of in vitro diagnostic (IVD) medical devices (IVD-MDs). More broadly, the scientific and medical communities use EQA data to demonstrate that medical laboratory examination procedures are fit for clinical purposes, to evaluate common reference intervals, and inclusion of data in clinical databases. Scientific groups, the IVD industry, reference laboratories and National Metrology Institutes can work with EQA providers to identify measurands, which should urgently be supported by the development of reference materials or methods. The ability of health systems to respond effectively to fast-evolving medical challenges, such as the Coronavirus Disease-19 (COVID-19) pandemic, is reliant on EQA to demonstrate confidence in the performance of new laboratory methods and testing services. EQA providers are uniquely positioned to assess the performance of IVD-MDs in addition to individual laboratories and testing sites. Although the primary focus of EQA providers remains the improvement of the performance of individual laboratories, there are many stakeholders who benefit from EQA performance data.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 859-867
Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part II – EQA cycles
External quality assessment (EQA) cycles are the smallest complete units within EQA programs that laboratories can use to obtain external assessments of their performance. In each cycle, several samples are distributed to the laboratories registered for participation, and ideally, EQA programs not only cover the examination procedures but also the pre- and post-examination procedures. The properties and concentration range of measurands in individual samples are selected with regard to the intended challenge for the participants so that each sample fulfils its purpose. This aims to ensure the most significant possible information gain in every cycle using the lowest possible number of EQA samples and thus, under economically optimal conditions. Participants examine samples and the results are reported to the EQA provider, who compares them with the target values for individual measurands in every sample. The EQA provider assesses the laboratory performance, and finally communicates the assessment results to the participant. The participants evaluate the outcomes of the assessment of their examination results and can draw conclusions in the case of both failing and passing and, if necessary, define improvement measures. After completion, each cycle is evaluated by the provider so that limitations and weaknesses of the EQA program can be identified and appropriate measures taken, or to confirm its continued suitability and appropriateness.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 859-867
Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part II – EQA cycles
External quality assessment (EQA) cycles are the smallest complete units within EQA programs that laboratories can use to obtain external assessments of their performance. In each cycle, several samples are distributed to the laboratories registered for participation, and ideally, EQA programs not only cover the examination procedures but also the pre- and post-examination procedures. The properties and concentration range of measurands in individual samples are selected with regard to the intended challenge for the participants so that each sample fulfils its purpose. This aims to ensure the most significant possible information gain in every cycle using the lowest possible number of EQA samples and thus, under economically optimal conditions. Participants examine samples and the results are reported to the EQA provider, who compares them with the target values for individual measurands in every sample. The EQA provider assesses the laboratory performance, and finally communicates the assessment results to the participant. The participants evaluate the outcomes of the assessment of their examination results and can draw conclusions in the case of both failing and passing and, if necessary, define improvement measures. After completion, each cycle is evaluated by the provider so that limitations and weaknesses of the EQA program can be identified and appropriate measures taken, or to confirm its continued suitability and appropriateness.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 844-858
Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part I – EQA in general and EQA programs in particular
This is the first in a series of five papers that detail the role and substantial impact that external quality assessment (EQA) and their providers‘ services play in ensuring in-vitro diagnostic (IVD) performance quality. The aim is to give readers and users of EQA services an insight into the processes in EQA, explain to them what happens before EQA samples are delivered and after examination results are submitted to the provider, how they are assessed, what benefits participants can expect, but also who are stakeholders other than participants and what significance do EQA data and assessment results have for them. This first paper presents the history of EQA, insights into legal, financing and ethical matters, information technology used in EQA, structure and lifecycle of EQA programs, frequency and intensity of challenges, and unique requirements of extra-examination and educational EQA programs.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 844-858
Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part I – EQA in general and EQA programs in particular
This is the first in a series of five papers that detail the role and substantial impact that external quality assessment (EQA) and their providers‘ services play in ensuring in-vitro diagnostic (IVD) performance quality. The aim is to give readers and users of EQA services an insight into the processes in EQA, explain to them what happens before EQA samples are delivered and after examination results are submitted to the provider, how they are assessed, what benefits participants can expect, but also who are stakeholders other than participants and what significance do EQA data and assessment results have for them. This first paper presents the history of EQA, insights into legal, financing and ethical matters, information technology used in EQA, structure and lifecycle of EQA programs, frequency and intensity of challenges, and unique requirements of extra-examination and educational EQA programs.
- Open Access
- 3 October 2024
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 73 (10) , 001915
Identification methods as a factor affecting the performance of clinical microbiology laboratories participating in an external quality assessment program: a cross-sectional, retrospective analysis
Introduction. Laboratory participation in external quality assessment (EQA) programmes including proficiency testing (PT) is a requirement of clinical laboratory conformance to ISO 15189:2022 Medical laboratories – Requirements for quality and competence . PT is one EQA method whereby laboratories are sent blinded samples for characterization by routine laboratory diagnostic methods. Importantly, PT enables a laboratory’s performance to be evaluated in comparison to the standard reference methods and to the performance of other peer laboratories using similar diagnostic methods. Gap statement. The desired outcome of participating in PT is to help laboratories identify possible sources of error in each step of the total testing process and particularly in their test methods during the analytical phase. Aim. This cross-sectional study investigated the impact of using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) compared to conventional phenotypic biochemical testing on laboratory performance in a clinical bacteriology PT scheme. Methodology. During a 6-year period from 2017-2022, the Canadian Microbiology Proficiency Testing implemented 112 PT challenges comprising 22 different sample types and included 61 different bacterial species. This was translated into 5883 graded test events for analysis. Multiple logistic regression techniques were employed to explore the association between the test method employed and laboratory performance. The sample type and aerobic classification of challenge organisms were included as confounding variables. Results. Laboratories using MALDI-TOF MS performed significantly better in characterizing microorganisms than laboratories using phenotypic biochemical testing alone [odds ratio OR = 5.68, confidence interval (CI): 3.92, 8.22] regardless of the sample type and aerobic classification. Notably, our analysis identified a significant association between anaerobic organisms and laboratory performance (OR: 0.24, CI: 0.17–0.35), suggesting that culturing and identifying fastidious organisms remains a significant obstacle for many clinical microbiology laboratories. Conclusions. Although no method is infallible and its performance will depend on the validation and quality assurance procedures, this finding may help the management in the decision for implementing MALDI-TOF MS in the microbiology laboratory. This study highlights the important role PT providers play in the objective assessment of laboratory performance and how it can provide evidence for quality improvement.
- 3 October 2024
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 73 (10) , 001915
Open AccessIdentification methods as a factor affecting the performance of clinical microbiology laboratories participating in an external quality assessment program: a cross-sectional, retrospective analysis
Introduction. Laboratory participation in external quality assessment (EQA) programmes including proficiency testing (PT) is a requirement of clinical laboratory conformance to ISO 15189:2022 Medical laboratories – Requirements for quality and competence . PT is one EQA method whereby laboratories are sent blinded samples for characterization by routine laboratory diagnostic methods. Importantly, PT enables a laboratory’s performance to be evaluated in comparison to the standard reference methods and to the performance of other peer laboratories using similar diagnostic methods. Gap statement. The desired outcome of participating in PT is to help laboratories identify possible sources of error in each step of the total testing process and particularly in their test methods during the analytical phase. Aim. This cross-sectional study investigated the impact of using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) compared to conventional phenotypic biochemical testing on laboratory performance in a clinical bacteriology PT scheme. Methodology. During a 6-year period from 2017-2022, the Canadian Microbiology Proficiency Testing implemented 112 PT challenges comprising 22 different sample types and included 61 different bacterial species. This was translated into 5883 graded test events for analysis. Multiple logistic regression techniques were employed to explore the association between the test method employed and laboratory performance. The sample type and aerobic classification of challenge organisms were included as confounding variables. Results. Laboratories using MALDI-TOF MS performed significantly better in characterizing microorganisms than laboratories using phenotypic biochemical testing alone [odds ratio OR = 5.68, confidence interval (CI): 3.92, 8.22] regardless of the sample type and aerobic classification. Notably, our analysis identified a significant association between anaerobic organisms and laboratory performance (OR: 0.24, CI: 0.17–0.35), suggesting that culturing and identifying fastidious organisms remains a significant obstacle for many clinical microbiology laboratories. Conclusions. Although no method is infallible and its performance will depend on the validation and quality assurance procedures, this finding may help the management in the decision for implementing MALDI-TOF MS in the microbiology laboratory. This study highlights the important role PT providers play in the objective assessment of laboratory performance and how it can provide evidence for quality improvement.
- Open Access
- 1 May 2024
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 11, 1338549
Improving drinking water quality through proficiency testing—the impact of testing method and accreditation status on Escherichia coli detection by Canadian environmental testing laboratories
Water quality testing is crucial for protecting public health, especially considering the number of boil water advisories annually issued across Canada that impact daily life for residents in affected areas. To overcome these challenges, the development of drinking water safety plans and accessibility to regular testing using simple, rapid, and accurate materials are necessary. However, the significance of monitoring the accuracy of environmental microbiology testing laboratories cannot be overlooked. Participation in external quality assessment programs, such as those that include proficiency testing (PT), is a necessary risk management resource that ensures the effectiveness of these testing processes. Proficiency Testing Canada (PTC), in collaboration with the Canadian Microbiological Proficiency Testing (CMPT) program based at the University of British Columbia, have implemented a drinking-water microbiology PT program since 1996. Both PTC and CMPT are ISO/IEC 17043:2010-accredited EQA providers. The drinking water program provided PT challenges to subscribing testing laboratories twice per year. Each challenge consisted of four samples containing unknown concentrations of Escherichia coli (E. coli) and Enterobacter spp. Results from participants were assessed for accuracy based on the method of testing. This cross-sectional study evaluated 150 rural and metropolitan testing sites across Canada between 2016 and 2022. Multivariable logistic regression analysis was conducted to examine the impact of different testing methods and laboratory accreditation status on the proficiency scores. This approach enabled us to assess the association between multiple independent variables and the likelihood of achieving specific proficiency scores, providing insights into how testing methods and accreditation status affect overall performance. After adjusting for rural residence, testing time, and survey year, the membrane filtration method was positively associated with the likelihood of scoring satisfactory results compared to the enzyme-substrate method (OR: 1.75; CI: 1.37–2.24), as well as accreditation status (OR: 1.47; CI: 1.16–1.85). The potential for improvement in environmental laboratory testing performance through the implementation of regulated PT in drinking water safety plans is proposed, along with the need for reliable testing methods applicable to rapid drinking water microbiology testing.
- 1 May 2024
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 11, 1338549
Open AccessImproving drinking water quality through proficiency testing—the impact of testing method and accreditation status on Escherichia coli detection by Canadian environmental testing laboratories
Water quality testing is crucial for protecting public health, especially considering the number of boil water advisories annually issued across Canada that impact daily life for residents in affected areas. To overcome these challenges, the development of drinking water safety plans and accessibility to regular testing using simple, rapid, and accurate materials are necessary. However, the significance of monitoring the accuracy of environmental microbiology testing laboratories cannot be overlooked. Participation in external quality assessment programs, such as those that include proficiency testing (PT), is a necessary risk management resource that ensures the effectiveness of these testing processes. Proficiency Testing Canada (PTC), in collaboration with the Canadian Microbiological Proficiency Testing (CMPT) program based at the University of British Columbia, have implemented a drinking-water microbiology PT program since 1996. Both PTC and CMPT are ISO/IEC 17043:2010-accredited EQA providers. The drinking water program provided PT challenges to subscribing testing laboratories twice per year. Each challenge consisted of four samples containing unknown concentrations of Escherichia coli (E. coli) and Enterobacter spp. Results from participants were assessed for accuracy based on the method of testing. This cross-sectional study evaluated 150 rural and metropolitan testing sites across Canada between 2016 and 2022. Multivariable logistic regression analysis was conducted to examine the impact of different testing methods and laboratory accreditation status on the proficiency scores. This approach enabled us to assess the association between multiple independent variables and the likelihood of achieving specific proficiency scores, providing insights into how testing methods and accreditation status affect overall performance. After adjusting for rural residence, testing time, and survey year, the membrane filtration method was positively associated with the likelihood of scoring satisfactory results compared to the enzyme-substrate method (OR: 1.75; CI: 1.37–2.24), as well as accreditation status (OR: 1.47; CI: 1.16–1.85). The potential for improvement in environmental laboratory testing performance through the implementation of regulated PT in drinking water safety plans is proposed, along with the need for reliable testing methods applicable to rapid drinking water microbiology testing.